Llwytho...
Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics
Up to 30% of people with schizophrenia do not respond to two (or more) trials of dopaminergic antipsychotics. They are said to have treatment-resistant schizophrenia (TRS). Clozapine is still the only effective treatment for TRS, although it is underused in clinical practice. Initial use is delayed,...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Pharmgenomics Pers Med |
|---|---|
| Prif Awduron: | , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Dove Medical Press
2016
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5106233/ https://ncbi.nlm.nih.gov/pubmed/27853387 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PGPM.S115741 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|